USFDA delays at Monroe and Goa facilities
Monroe facility has an FDA meeting in September 2024, but no restart timeline; Goa remediation completed but inspection pending. Delays could impact US launches.
GLENMARK / Q1-FY25 / risks
Keep the risk register visible.
Glenmark Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
GLP-1 market shift post-2026
Semaglutide patent expiry in 2026 may shift patients from liraglutide to newer GLP-1s, potentially limiting liraglutide's revenue potential.
Working capital increase
CFO guided working capital days to increase to ~75 days from current 62 days, driven by business growth and receivables, which could pressure cash flows.